Living with Alzheimer's disease is a journey marked by changing memories and abilities. Researchers are looking closely at how genetics play a role in how the disease progresses. A recent look at data from a Phase 3 clinical trial focused on a specific gene called APOE epsilon 4 to see if it changed how fast patients lost their memory over time.
The study followed 343 people with mild to moderate Alzheimer's. They compared people who carried the APOE epsilon 4 gene to those who did not. While people with the gene had worse scores overall at the start, the study found that they did not actually decline faster than those without the gene over the 80-week period. The difference in the rate of decline was not statistically significant.
It is important to note that this analysis only looked at the group that did not receive the active medication. While the gene was linked to how severe the disease was when the study began, it did not predict how quickly the condition would worsen. Because this was a smaller subset of a larger trial, the results are specific to this group of patients.
